CDH6-activated αIIbβ3 crosstalks with α2β1 to trigger cellular adhesion and invasion in metastatic ovarian and renal cancers.


Journal

Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230

Informations de publication

Date de publication:
07 2021
Historique:
revised: 25 01 2021
received: 14 09 2020
accepted: 12 03 2021
pubmed: 15 3 2021
medline: 8 4 2022
entrez: 14 3 2021
Statut: ppublish

Résumé

Cadherin 6 (CDH6) is significantly overexpressed in advanced ovarian and renal cancers. However, the role of CDH6 in cancer metastasis is largely unclear. Here, we investigated the impact of CDH6 expression on integrin-mediated metastatic progression. CDH6 preferentially bound to αIIbβ3 integrin, a platelet receptor scarcely expressed in cancer cells, and this interaction was mediated through the cadherin Arginine-glycine-aspartic acid (RGD) motif. Furthermore, CDH6 and CDH17 were found to interact with α2β1 in αIIbβ3

Identifiants

pubmed: 33715292
doi: 10.1002/1878-0261.12947
pmc: PMC8253092
doi:

Substances chimiques

Cadherins 0
Integrin alpha2beta1 0
Platelet Glycoprotein GPIIb-IIIa Complex 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1849-1865

Informations de copyright

© 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

Références

Cancer. 2007 Sep 15;110(6):1272-80
pubmed: 17634950
J Cell Biol. 1998 Jun 15;141(6):1467-76
pubmed: 9628901
Semin Oncol. 2014 Jun;41(3):378-84
pubmed: 25023353
Oncogene. 2017 Oct 19;36(42):5840-5851
pubmed: 28628116
Oncotarget. 2017 Jan 3;8(1):215-227
pubmed: 27966446
Cancer Res. 1996 Nov 1;56(21):5071-8
pubmed: 8895766
Nat Cell Biol. 2002 Apr;4(4):E65-8
pubmed: 11944032
PLoS Med. 2008 Dec 2;5(12):e232
pubmed: 19053170
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Cancers (Basel). 2017 Sep 28;9(10):
pubmed: 28956830
Blood. 2007 Jan 15;109(2):595-602
pubmed: 16985184
Oncogene. 2014 Mar 27;33(13):1658-69
pubmed: 23604127
J Biol Chem. 2014 Dec 12;289(50):34801-14
pubmed: 25336636
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Trends Cancer. 2015 Sep;1(1):76-91
pubmed: 28741564
Cancer Res. 1997 Jul 1;57(13):2741-8
pubmed: 9205085
Cancer Discov. 2017 Sep;7(9):1030-1045
pubmed: 28526733
Asian J Urol. 2016 Oct;3(4):286-292
pubmed: 29264197
Cell. 2017 Feb 9;168(4):670-691
pubmed: 28187288
Prostate. 1998 May 15;35(3):185-92
pubmed: 9582087
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14205-10
pubmed: 14612570
Br J Cancer. 1995 Feb;71(2):376-9
pubmed: 7841055
Thromb Haemost. 2002 Nov;88(5):858-64
pubmed: 12428106
Int J Cancer. 2002 Sep 10;101(2):156-67
pubmed: 12209993
Cell Signal. 2010 Apr;22(4):578-83
pubmed: 19874888
Cancer Genomics Proteomics. 2016 11-12;13(6):407-423
pubmed: 27807064
Mod Pathol. 2011 Jun;24(6):751-64
pubmed: 21317881
Int J Mol Sci. 2019 Jul 09;20(13):
pubmed: 31324051
Clin Cancer Res. 2018 Jan 15;24(2):433-444
pubmed: 28916526
Clin Cancer Res. 1999 Sep;5(9):2485-90
pubmed: 10499623
Cancer Res. 2008 Apr 1;68(7):2329-39
pubmed: 18381440
Thromb Haemost. 2003 Sep;90(3):549-54
pubmed: 12958625
Oncotarget. 2016 Jul 5;7(27):41929-41947
pubmed: 27259239
Arterioscler Thromb Vasc Biol. 2012 Jul;32(7):1724-31
pubmed: 22539596
Blood. 2010 Apr 29;115(17):3427-36
pubmed: 20194899
Mol Biol Cell. 1996 Dec;7(12):1939-51
pubmed: 8970156
Am J Physiol Cell Physiol. 2015 Oct 1;309(7):C444-56
pubmed: 26224579
Cancer Res. 1994 Aug 15;54(16):4532-8
pubmed: 8044804
Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):321-332
pubmed: 29673969
Br J Dermatol. 1996 Dec;135(6):883-7
pubmed: 8977707
Oncogene. 2011 Mar 31;30(13):1566-76
pubmed: 21119598
Br J Cancer. 2014 Jan 7;110(1):123-32
pubmed: 24178762
Trends Cell Biol. 2014 Sep;24(9):524-36
pubmed: 24794279
J Microsc. 2006 Dec;224(Pt 3):213-32
pubmed: 17210054
Clin Cancer Res. 2018 Jan 15;24(2):253-255
pubmed: 29084915
Cancer Biol Med. 2017 Feb;14(1):9-32
pubmed: 28443200
PLoS One. 2013 Sep 12;8(9):e75489
pubmed: 24069422
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Pharmacol Exp Ther. 2001 Mar;296(3):690-6
pubmed: 11181894
Int J Cancer. 1995 Dec 20;64(6):407-14
pubmed: 8550243
Cancer. 2004 Sep 1;101(5):963-8
pubmed: 15329904

Auteurs

Rubén A Bartolomé (RA)

Department of Biomolecular Medicine, Centro de Investigaciones Biológicas, CSIC, Madrid, Spain.

Javier Robles (J)

Department of Biomolecular Medicine, Centro de Investigaciones Biológicas, CSIC, Madrid, Spain.

Ángela Martin-Regalado (Á)

Department of Biomolecular Medicine, Centro de Investigaciones Biológicas, CSIC, Madrid, Spain.

Laura Pintado-Berninches (L)

Department of Biomolecular Medicine, Centro de Investigaciones Biológicas, CSIC, Madrid, Spain.

Miranda Burdiel (M)

Department of Biomolecular Medicine, Centro de Investigaciones Biológicas, CSIC, Madrid, Spain.

Marta Jaén (M)

Department of Biomolecular Medicine, Centro de Investigaciones Biológicas, CSIC, Madrid, Spain.

Carmen Aizpurúa (C)

Protein Alternatives SL, Tres Cantos, Spain.

Juan I Imbaud (JI)

Protein Alternatives SL, Tres Cantos, Spain.

José Ignacio Casal (JI)

Department of Biomolecular Medicine, Centro de Investigaciones Biológicas, CSIC, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH